Adenocarcinoma Lung Cancer Completed Phase 2 Trials for Ceritinib (DB09063)

IndicationStatusPhase
DBCOND0072925 (Adenocarcinoma Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02276027A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerTreatment